leflunomide has been researched along with Diffuse Parenchymal Lung Disease in 30 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not respond well to standard RA treatment." | 7.81 | Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis. ( Chazan, R; Karwat, K; Langfort, R; Maskey-Warzęchowska, M; Szczepankiewicz, B; Szołkowska, M, 2015) |
| "Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently." | 7.73 | Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. ( Ernst, P; Hudson, M; Suissa, S, 2006) |
| "A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide." | 7.72 | Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. ( Haneda, K; Iwamoto, M; Kamata, Y; Kamimura, T; Masuyama, J; Minota, S; Nara, H; Okazaki, H, 2004) |
| "Leflunomide (LEF) is a frequently prescribed disease-modifying antirheumatic drug for treating RA." | 6.53 | Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review. ( Chung, KP; Huang, HN; Keng, LT; Lin, MW, 2016) |
| "Leflunomide is an effective DMARD that sustains a clinical and radiological response comparable to sulfasalazine and methotrexate." | 6.45 | Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. ( Alcorn, N; Madhok, R; Saunders, S, 2009) |
| "The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern." | 5.35 | Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2009) |
| "Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not respond well to standard RA treatment." | 3.81 | Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis. ( Chazan, R; Karwat, K; Langfort, R; Maskey-Warzęchowska, M; Szczepankiewicz, B; Szołkowska, M, 2015) |
| "A 60-year-old rheumatoid arthritis (RA) female with lung fibrosis was treated with leflunomide (LEF) for only 12 days, and responded well." | 3.74 | Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. ( Harada, M; Inokuma, S; Koyama, T; Niiro, H; Ohtani, R; Otsuka, T; Yoshizawa, S, 2008) |
| "We describe a 54-year-old woman with rheumatoid arthritis (RA), who developed acute respiratory failure 2 weeks after cessation of 6-week treatment with leflunomide." | 3.73 | Leflunomide induced acute interstitial pneumonia. ( Adachi, D; Akiba, H; Akiyama, Y; Hirano, M; Mimura, T; Takeishi, M, 2005) |
| "Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently." | 3.73 | Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. ( Ernst, P; Hudson, M; Suissa, S, 2006) |
| "A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide." | 3.72 | Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. ( Haneda, K; Iwamoto, M; Kamata, Y; Kamimura, T; Masuyama, J; Minota, S; Nara, H; Okazaki, H, 2004) |
| "Leflunomide (LEF) is a frequently prescribed disease-modifying antirheumatic drug for treating RA." | 2.53 | Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review. ( Chung, KP; Huang, HN; Keng, LT; Lin, MW, 2016) |
| "The pathogenesis of DMARD-induced lung injury may have common features that need to be clarified in the future." | 2.47 | Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury. ( Inokuma, S, 2011) |
| "Two patients had previous MTX-induced pneumonitis (MTX-P) prior to initiation of LEF; both died from LEIP." | 2.45 | Clinical expression of leflunomide-induced pneumonitis. ( Chikura, B; Dawson, JK; Lane, S, 2009) |
| "Leflunomide is an effective DMARD that sustains a clinical and radiological response comparable to sulfasalazine and methotrexate." | 2.45 | Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. ( Alcorn, N; Madhok, R; Saunders, S, 2009) |
| "Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE)." | 1.43 | [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus]. ( Jia, Y; Miao, H; Wang, L; Yang, Y; Zhang, XY; Zhou, YS, 2016) |
| "Leflunomide (LEF)-induced interstitial lung disease (ILD) has been reported in patients with rheumatoid arthritis." | 1.37 | Interstitial lung diseases after leflunomide use in nephropathy: an analysis of reported cases in Chinese literature. ( Zhang, WX; Zhang, ZQ; Zhao, XW; Zhou, W, 2011) |
| "The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern." | 1.35 | Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (60.00) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JW | 3 |
| Chung, SW | 3 |
| Pyo, JY | 3 |
| Chang, SH | 3 |
| Kim, MU | 3 |
| Park, CH | 3 |
| Lee, JS | 6 |
| Ha, YJ | 3 |
| Kang, EH | 3 |
| Lee, YA | 3 |
| Park, YB | 3 |
| Lee, EY | 3 |
| Choe, JY | 4 |
| Cano-Jiménez, E | 1 |
| Vázquez Rodríguez, T | 1 |
| Martín-Robles, I | 1 |
| Castillo Villegas, D | 1 |
| Juan García, J | 1 |
| Bollo de Miguel, E | 1 |
| Robles-Pérez, A | 1 |
| Ferrer Galván, M | 1 |
| Mouronte Roibas, C | 1 |
| Herrera Lara, S | 1 |
| Bermudo, G | 1 |
| García Moyano, M | 1 |
| Rodríguez Portal, JA | 1 |
| Sellarés Torres, J | 1 |
| Narváez, J | 1 |
| Molina-Molina, M | 1 |
| Atzeni, F | 1 |
| Boiardi, L | 1 |
| Sallì, S | 1 |
| Benucci, M | 1 |
| Sarzi-Puttini, P | 1 |
| Rutanen, J | 1 |
| Kononoff, A | 1 |
| Arstila, L | 1 |
| Elfving, P | 1 |
| Koskela, H | 1 |
| Kaipiainen-Seppänen, O | 1 |
| Maskey-Warzęchowska, M | 1 |
| Karwat, K | 1 |
| Szczepankiewicz, B | 1 |
| Langfort, R | 1 |
| Szołkowska, M | 1 |
| Chazan, R | 1 |
| Keng, LT | 1 |
| Lin, MW | 1 |
| Huang, HN | 1 |
| Chung, KP | 1 |
| Wang, L | 1 |
| Yang, Y | 1 |
| Jia, Y | 1 |
| Miao, H | 1 |
| Zhou, YS | 1 |
| Zhang, XY | 1 |
| Chikura, B | 1 |
| Lane, S | 1 |
| Dawson, JK | 2 |
| Sawada, T | 2 |
| Inokuma, S | 4 |
| Sato, T | 2 |
| Otsuka, T | 3 |
| Saeki, Y | 2 |
| Takeuchi, T | 2 |
| Matsuda, T | 2 |
| Takemura, T | 2 |
| Sagawa, A | 2 |
| Alcorn, N | 1 |
| Saunders, S | 1 |
| Madhok, R | 1 |
| Wong, SP | 1 |
| Chu, CM | 1 |
| Kan, CH | 1 |
| Tsui, HS | 1 |
| Ng, WL | 1 |
| Lee, MA | 1 |
| Hutchinson, DG | 1 |
| McLaren, ZL | 1 |
| Zhang, WX | 1 |
| Zhou, W | 1 |
| Zhang, ZQ | 1 |
| Zhao, XW | 1 |
| Mohr, M | 1 |
| Jacobi, AM | 1 |
| McCurry, J | 1 |
| Scott, DL | 1 |
| Ito, S | 1 |
| Sumida, T | 1 |
| Kamata, Y | 1 |
| Nara, H | 1 |
| Kamimura, T | 1 |
| Haneda, K | 1 |
| Iwamoto, M | 1 |
| Masuyama, J | 1 |
| Okazaki, H | 1 |
| Minota, S | 1 |
| Nakajima, A | 1 |
| Yamanaka, H | 1 |
| Sugii, S | 1 |
| Takeishi, M | 1 |
| Akiyama, Y | 1 |
| Akiba, H | 1 |
| Adachi, D | 1 |
| Hirano, M | 1 |
| Mimura, T | 1 |
| Suissa, S | 1 |
| Hudson, M | 1 |
| Ernst, P | 1 |
| Kudo, S | 1 |
| Sugiyama, Y | 1 |
| Chida, K | 1 |
| Ogura, T | 1 |
| Yamaguchi, T | 1 |
| Miyazaki, K | 1 |
| Ochi, S | 1 |
| Harigai, M | 1 |
| Mizoguchi, F | 1 |
| Iwai, H | 1 |
| Hagiyama, H | 1 |
| Oka, T | 1 |
| Miyasaka, N | 1 |
| Ju, JH | 1 |
| Kim, SI | 1 |
| Lee, JH | 1 |
| Lee, SI | 1 |
| Yoo, WH | 1 |
| Chung, SH | 1 |
| Lee, J | 1 |
| Lee, YH | 1 |
| Lee, SS | 1 |
| Yoon, HJ | 1 |
| Yoon, CH | 1 |
| Kim, HY | 1 |
| Park, SH | 1 |
| Koyama, T | 1 |
| Ohtani, R | 1 |
| Niiro, H | 1 |
| Yoshizawa, S | 1 |
| Harada, M | 1 |
8 reviews available for leflunomide and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
Topics: Antibodies, Blocking; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheum | 2013 |
Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review.
Topics: Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunom | 2016 |
Clinical expression of leflunomide-induced pneumonitis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; | 2009 |
Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interactions; Drug Therapy, Combination; | 2009 |
Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury.
Topics: Animals; Antirheumatic Agents; Humans; Isoxazoles; Japan; Leflunomide; Lung Diseases, Interstitial; | 2011 |
[Leflunomide for therapy of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Is | 2005 |
[Adverse effects of DMARDs in treatment of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; Hematologic Diseases; H | 2005 |
[Drug induced lung injuries in Japanese population].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Asian People; Bleomycin; Gefitinib; Genetic Predisposi | 2006 |
22 other studies available for leflunomide and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies | 2021 |
Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy.
Topics: Aged; Arthritis, Rheumatoid; Disease Progression; Drug Interactions; Drug Therapy, Combination; Fema | 2014 |
Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Fatal Outcome; Humans; Isoxazoles; Leflunomide; Lung | 2015 |
[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinucle | 2016 |
Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Body Weight; Female; Humans; Isoxazoles; Japan; L | 2009 |
Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.
Topics: Aged; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Crotonates | 2009 |
Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy.
Topics: Adult; Alveolitis, Extrinsic Allergic; Anion Exchange Resins; Antirheumatic Agents; Arthritis, Rheum | 2009 |
HRCT-proven leflunomide pneumonitis in a patient with psoriatic arthritis and normal lung function tests and chest radiography.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Female; Humans; Isoxazoles; Leflunomide; Lung Diseases, | 2010 |
Comment on: Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Cause of Death; Humans; Isoxazoles; Japan | 2010 |
Interstitial lung diseases after leflunomide use in nephropathy: an analysis of reported cases in Chinese literature.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Child; China; Female; Humans; IgA Vasculitis; Isoxazo | 2011 |
Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Bronchoalveolar Lava | 2011 |
Japan deaths spark concerns over arthritis drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cause of Death; Drug Approval; Human | 2004 |
Interstitial lung disease and disease modifying anti-rheumatic drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxaz | 2004 |
Interstitial lung disease associated with leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Lun | 2004 |
Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Eruptions; Human | 2004 |
Leflunomide induced acute interstitial pneumonia.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Cholestyramine Resin; Drug Therapy, Combination; Fema | 2005 |
Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Isoxazoles; Leflunomide | 2006 |
[Diagnosis of and therapy for diffuse lung diseases (discussion)].
Topics: Alveolitis, Extrinsic Allergic; Biomarkers; Bronchiolitis; Gefitinib; Humans; Isoxazoles; Leflunomid | 2006 |
Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Autopsy; Cholestyramine | 2006 |
Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Korea; Leflunomide; Lung Di | 2007 |
Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Administration Schedule; Female | 2008 |